Navigation Links
The Michael J. Fox Foundation and Imago Pharmaceuticals Partner to Advance Use of Research Tools to Speed Parkinson's Research
Date:5/11/2015

NEW YORK, May 11, 2015 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces the acquisition of a library of research tools around the parkin protein from Imago Pharmaceuticals. The Foundation believes these tools — cell lines, plasmids, compounds and more — will accelerate biological study and drug development against this promising disease-modification target.

Imago purchased the tools as part of a deal with health firm Perrigo in late 2014. These parkin assets originated at now-defunct biotech Elan Pharmaceuticals, where Imago leaders worked on another target: c-Jun N-terminal kinase, or JNK. They are continuing work on JNK inhibitors as potential therapeutics for inflammatory, autoimmune and neurodegenerative diseases, including Parkinson's disease.

MJFF bought hundreds of parkin tools for a cost covering storage and shipment. Foundation staff and advisors are now strategizing where to invest in further testing and replication.

"We're immensely grateful to Imago for offering this valuable library of varied research tools," said Marco Baptista, PhD, who leads the MJFF Parkin Program. "The availability of these resources will significantly speed parkin research and the field's ability to test new concepts toward a therapy that may have clinical relevance for millions living with Parkinson's disease."

The research tools deemed most valuable will join the MJFF Research Tools Catalog, a listing of assets from antibodies to viral vectors managed by the Foundation. MJFF makes these tools easily and affordably available to the research community to break down barriers to progress and advance Parkinson's discovery and drug development.

"We believe that there is substantial value in the Parkin Program assets and that The Michael J. Fox Foundation is uniquely positioned to maximize this value," said Irene Griswold-Prenner, PhD, Co-Founder and CSO of Imago Pharmaceuticals. "The Parkin Program was developed at Elan, where significant time and resources were invested in this program. With MJFF making the parkin reagents broadly available to the Parkinson's disease research community, these reagents can be maximally utilized and increase the probability of benefiting Parkinson's patients."

The parkin protein is a target of interest for researchers seeking to develop treatments to slow or stop progression of Parkinson's disease, an unmet need. Currently available therapies treat only the symptoms of the disease.

Mutations in the parkin (PARK2) gene are associated with young-onset Parkinson's disease and lead to dysfunction of the parkin protein. Scientists believe that the protein plays a role in mitophagy and mitochondrial function and that parkin levels are reduced as we age. MJFF is funding a consortia of investigators studying the biology of parkin and the development of both parkin replacement and activation therapies for those with the PARK2 mutation and with other forms of Parkinson's disease (i.e., sporadic, associated with other genetic mutations), respectively.

The Foundation will work with funded researchers to fold the parkin tools into their studies first then roll them out to the greater research community later this year.

About The Michael J. Fox Foundation for Parkinson's Research
As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers.  In addition to funding more than $450 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

For more information, visit us on the Web, Facebook, Twitter, LinkedIn and Pinterest.

About Imago Pharmaceuticals
Imago Pharmaceuticals, a privately held pharmaceutical company, engages in preclinical and clinical development of drug candidates directed against targets implicated in inflammatory, autoimmune and neurodegenerative diseases.

For more information, please visit our website at www.imago-pharma.com.

 


'/>"/>
SOURCE The Michael J. Fox Foundation; Imago Pharmaceuticals
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
2. Promising Parkinsons Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
3. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
4. Red Carpet Star Studded Celebrity Gala in Partnership with the Michael J. Fox Foundation for Parkinsons Research
5. Health Decisions CEO Michael Rosenberg, MD, MPH, Offers Insights into Adaptive and Risk-Based Monitoring in the Journal of Clinical Research Best Practices
6. Michael Walton Retires From The Female Health Company Board of Directors
7. Dr. Michael Feiz on What Makes a Great Bariatric Physician
8. The Michael J. Fox Foundation Leads Charge to Develop Alpha-Synuclein PET Tracer to Image Parkinsons Disease Biomarker
9. Iniziativa della Michael J. Fox Foundation in collaborazione con la Fondazione Grigioni: Parkinson, arriva anche in Italia il "Fox Trial Finder" per i pazienti accesso gratuito alle nuovi cure
10. Highmark executive Michael Fiaschetti Appointed to Board of Pennsylvania eHealth Partnership Authority
11. Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2019)... ... September 18, 2019 , ... NDA Partners Chairman ... well-respected preclinical drug development expert with a focus in the cardiovascular and metabolic ... to joining NDA Partners, Dr. Hoffmann served as Executive Director of Preclinical Safety ...
(Date:9/17/2019)... New Zealand (PRWEB) , ... September 17, 2019 , ... ... in in Fast Company’s 2019 Innovation by Design Awards Students category. , It was ... at the Auckland Bioengineering Institute. , Muss-Bits is comprised of two parts. A “sensor ...
(Date:9/17/2019)... ... 2019 , ... Scientists writing in a 2017 issue of ... progressive destruction of joint cartilage in osteoarthritis are “on the close horizon.” ... orthopedic surgeon Alejandro Badia, MD , founder and chief medical officer of ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... 17, 2019 , ... Caravan Health is seeking ... the country, the company announced today. High-performing community health systems and providers can ... cost efficiency. This opportunity is open to those new to value-based Medicare payment ...
(Date:9/17/2019)... PASO ROBLES, Calif. (PRWEB) , ... September 17, ... ... Pismo Beach , CA, recently announced that he has been certified by the ... Botox in dentistry is used to correct a wide range of orofacial conditions ...
(Date:9/17/2019)... BOSTON (PRWEB) , ... September 17, 2019 , ... ... Participation (CISCRP) is pleased to announce the release of the third edition of ... a comprehensive, easy-to-read guide for patients, caregivers and families to navigate the clinical ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... detection and treatment of infectious diseases at its annual Congress (WMIC) recently ... detection of residual HIV infected cell persistence and the development of pathogen-specific ...
(Date:9/11/2019)... ... September 12, 2019 , ... “Heart Seizures”: a useful ... coronary artery disease as he hopes to prevent anyone from having it and to ... author John Saltwick, a writer who was diagnosed with coronary artery disease. Predicted to ...
Breaking Medicine News(10 mins):